LOKARA SUMMARY
LoKara™ Lotion
(desonide lotion 0.05%)
LoKara™ Lotion (desonide lotion 0.05%) contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α-) a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic agents.
LoKara™ Lotion (desonide lotion 0.05%) is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
|
NEWS HIGHLIGHTS
Published Studies Related to Lokara (Desonide Topical)
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. [2007.02]
Low to mid potency corticosteroids remain a cornerstone of therapy for atopic dermatitis (AD)...
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. [2005.03]
CONCLUSION: The presence of 0.05% desonide does not impair or improve the Malassezia susceptibility to 2% ketoconazole when growing on lipid-enriched human stratum corneum. Copyright 2005 S. Karger AG, Basel.
Overview on desonide 0.05%: a clinical safety profile. [2004.07]
Desonide (as a cream, ointment, or lotion formulation) is widely used for the treatment of steroid-responsive dermatoses... The excellent safety profile of desonide revealed by this pharmacovigilance program is supported by a review of published clinical trial results.
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. [2002.08]
The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis...
Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. [2002.07]
PURPOSE: To study the safety and efficacy of the topical corticosteroid, desonide 0.25% ophthalmic solution, for inhibition of the clinical allergic reaction induced by conjunctival provocation (CPT) and for the treatment of seasonal allergic conjunctivitis (SAC)... CONCLUSIONS: Desonide has a significant therapeutic effect on both the induced conjunctival early- and late-allergic reaction and in active SAC. It was also safe, with no side effects such as increases in intraocular pressure observed by physician or patient.
Clinical Trials Related to Lokara (Desonide Topical)
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis [Not yet recruiting]
This study compares the effectiveness of two topical creams for atopic dermatitis in
pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice
daily for 6 weeks or until clear.
|
|
|
|
Page last updated: 2007-06-01
|
